Lisata Therapeutics, Inc.
LSTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.74 | 0.00 | 0.20 |
| FCF Yield | -14.60% | -15.85% | -26.72% | -18.24% |
| EV / EBITDA | 0.00 | -1.77 | -0.02 | -1.91 |
| Quality | ||||
| ROIC | 0.00% | -23.25% | -19.16% | -16.68% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.79 | 0.85 | 1.14 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,022,709.12% | 1,022,709.12% | 999,900.00% | 999,900.00% |
| Free Cash Flow Growth | 15.52% | 26.77% | -19.30% | -79.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 3.64 | 3.57 | 3.52 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 644.14 | -1,260.00 | 81.00 |